SD Biosensor Signs Tripartite MOU for R&D of New Products for XDR-TB with Japan’s RIT/JATA and Korea’s International Tuberculosis Research Center

6 December 2024

SEOUL, South Korea, Dec. 6, 2024 — SD Biosensor, Inc., South Korea’s global in-vitro diagnostics company, announced the signing of a tripartite memorandum of understanding (MOU) for the research and development (R&D) of new products targeting extensively drug-resistant tuberculosis (XDR-TB) using its Point-of-Care (POC) molecular diagnostic platform “STANDARD M10”. The MOU was signed with the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association (“RIT/JATA”), and Korea’s International Tuberculosis Research Center.

Read the full press release here.

Source: PR Newswire